Gan and Lee Pharmaceuticals, USA   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Beijing China (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2015
NCT02506647
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Gan and Lee Pharmaceuticals, USA | Gan & Lee Pharmaceuticals, USA | Gan & Lee Pharmaceuticals USA Corporation

Active Ingredients

Drugs in Phase 3 Trials (2)

insulin glargine (toujeo) (4 trials)

insulin lispro (humalog) (2 trials)

Drugs in Phase 2 Trials (1)

glr2007 (1 trial)

Drugs in Phase 1 Trials (2)

gzr-18 (1 trial)

insulin aspart (Novolog) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Glioblastoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 5